Filing Flows › AdvanSix (ASIX) › Q3 2026 › vs Q2 2026
AdvanSix (ASIX) Q3 2026 vs Q2 2026 (quarter over quarter)
AdvanSix's revenue rose $9.5M (+2%) from $421M in Q2 2026 to $431M in Q3 2026. The biggest changes: Chemical Intermediates −$23.3M (-18%); Plant Nutrients +$17.9M (+14%); Caprolactam +$10.4M (+17%).
AdvanSix, Q3 2026: revenue $431M (+15% year over year), operating margin -2.6%, net loss $7.6M, operating cash flow $48.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Plant Nutrients | $149M | $131M | $17.9M | +14% |
| Nylon | $105M | $100M | $4.5M | +5% |
| Chemical Intermediates | $104M | $127M | −$23.3M | -18% |
| Caprolactam | $73.1M | $62.6M | $10.4M | +17% |
| Revenue | $431M | $421M | $9.5M | +2% |
| Income tax benefit | $3.6M | −$3.4M | $7.0M | — |
| Net loss | $7.6M | −$3.2M | $10.8M | — |
| Costs & expenses | $442M | $421M | $20.7M | +5% |
| Operating costs | $442M | $415M | $27.3M | +7% |
| Cost of revenue | $420M | $390M | $29.4M | +8% |
| SG&A | $19.2M | $22.1M | −$2.9M | -13% |
| Other operating costs | $3.1M | $2.4M | $744K | +31% |
| Operating cash sources | $55.5M | $6.8M | $48.7M | +718% |
| Depreciation & amortization | $21.1M | $20.8M | $276K | +1% |
| Share-based compensation | $675K | $1.8M | −$1.2M | -63% |
| Working capital & other | $33.8M | −$15.8M | $49.6M | — |
| Net loss absorbed | $7.6M | −$3.2M | $10.8M | — |
| Operating cash flow | $48.0M | $10.0M | $37.9M | +378% |
Questions
How much did AdvanSix's revenue grow quarter over quarter in Q3 2026?
AdvanSix's revenue rose $9.5M (+2%) from $421M in Q2 2026 to $431M in Q3 2026.
What drove AdvanSix's revenue change in Q3 2026?
Chemical Intermediates −$23.3M (-18%); Plant Nutrients +$17.9M (+14%); Caprolactam +$10.4M (+17%).